PEGylated Protein Drugs: Basic Science and Clinical Applications

  • Francesco M. Veronese

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages I-IX
  2. Francesco M. Veronese, Anna Mero, Gianfranco Pasut
    Pages 11-31
  3. Gian Maria Bonora, Sara Drioli
    Pages 33-45
  4. Ji-Won Choi, Antony Godwin, Sibu Balan, Penny Bryant, Yuehua Cong, Estera Pawlisz et al.
    Pages 47-73
  5. Mauro Sergi, Francesca Caboi, Carlo Maullu, Gaetano Orsini, Giancarlo Tonon
    Pages 75-88
  6. Angelo Fontana, Barbara Spolaore, Anna Mero, Francesco M. Veronese
    Pages 89-112
  7. Rob Webster, Victoria Elliott, B. Kevin Park, Donald Walker, Mark Hankin, Philip Taupin
    Pages 127-146
  8. Michael S. Hershfield, John S. Sundy, Nancy J. Ganson, Susan J. Kelly
    Pages 217-227
  9. Andrew M. Nesbitt, Sue Stephens, Elliot K. Chartash
    Pages 229-254
  10. Anna Mero, Gianfranco Pasut, Francesco M. Veronese
    Pages 255-271
  11. Back Matter
    Pages 283-287

About this book

Introduction

PEGylated Protein Drugs: Basic Science and Clinical Applications describes the basic technologies and the major results obtained with the PEGylation technique, the covalent binding to proteins, peptides and small organic molecules of the hydrophilic and biocompatible polymer poly(ethylene glycol) to improve their therapeutic efficacy.

The book results from the collaboration of recognized experts from academia and industry, working on various aspects of the PEGylation technology. The first chapters provide general information on the physicochemical, pharmacokinetic, immunogenic and toxicological properties of PEG and PEG-conjugates. The classical and more advanced chemical strategies for linking PEG to protein drugs are described as well as novel enzyme-catalysed approaches. Further chapters are devoted to important PEGylated products, namely PEG conjugates of enzymes, cytokines, antibodies or synthetic organic molecules already on the market or in an advanced state of clinical experimentation. Guidelines for the approval by the Health Agencies of these new nanomedicines are also reported as a last chapter.

Therefore, this book may be a unique instrument for a thorough review of the strategy, advantages and limitations of all aspects of drug PEGylation as well as a stimulation for researchers to develop new exploitations of this technology. It is of interest to physicians, biochemists, pharmacologists and chemists.

Keywords

Nucleotide PEG preparation PEGylation technique Pegfilgrastim Protein conjugation cancer cancer therapy interferon necrosis pharmaceutical preparation protein proteins research toxicity

Editors and affiliations

  • Francesco M. Veronese
    • 1
  1. 1.Department of Pharmaceutical SciencesUniversity of PadovaPadovaItaly

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-7643-8679-5
  • Copyright Information Birkhäuser Basel 2009
  • Publisher Name Birkhäuser Basel
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-7643-8678-8
  • Online ISBN 978-3-7643-8679-5
  • About this book